MedWatch

Novo CEO: We want to focus on mature companies

It was a change in the strategy that led Novo A/S to sell the British company Archimedes Pharma to Prostrakan, a part of Japan-based group Kyowa Hakko Kirin, explains CEO Eivind Kolding.

Foto: LARS KRABBE

Novo A/S used to focus on companies in the early commercialization phases, but a change of that strategy to a focus on bigger and more mature companies led to the divestiture of British-based Archimedes Pharma.

“Our strategy going forward is to invest in some bigger and more mature companies than Achimedes. [The investment in Archimedes] came as the result of a different strategy where we focused on companies in the early commercialization phases. But we have moved away from that, so we chose to sell Archimedes. But also because the timing was right, both for the specific company and because the market is generally positive,” Eivind Kolding, CEO in Novo A/S, tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier